The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells

Maha S Al-Keilani,1 Karem H Alzoubi,1 Saied A Jaradat2,3 1Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan; 2Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan; 3P...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Al-Keilani MS, Alzoubi KH, Jaradat SA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://doaj.org/article/6d17358580134186b50e93e8fd057d06
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!